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ABSTRACT 
Background: 
Although reoperative surgery in the central compartment (RCND) is indicated in bulky or 
progressive persistent/recurrent papillary thyroid carcinoma (PTC), its associated morbidity and 
disease outcomes remain unclear. We aimed to evaluate these by comparing them with patients 
who underwent primary central neck dissection (CND). 
Methods: 
After matching for age, sex, tumor size and initial tumor stage, the morbidity and outcomes of 50 
consecutive patients who underwent RCND were compared with 75 patients who underwent 
primary therapeutic CND during the same period. Matching was performed blind to the 
morbidity and disease outcome of each patient. A stimulated thyroglobulin (sTg) < 2ng/mL was 
considered undetectable.  
Results: 
Relative to primary CND, the incidence of extranodal extension (p=0.010) and size of metastatic 
lymph nodes (p<0.001) were significantly greater in the RCND group. Postoperative 
hypoparathyroidism and vocal cord palsy rates were comparable in the two groups but there were 
two esophageal injuries in the RCND group and none in the primary CND group. The secondary 
CND group achieved significantly lower undetectable post-ablation sTg rate (12.0% vs. 
52.0%,p=0.001) and worse 10-year disease-free survival (35.6% vs. 91.8%, p=0.001) and 
cancer-specific survival (82.0% vs. 98.5%, p=0.001) than the primary CND group. 
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Conclusions: 
Although RCND for persistent / recurrent PTC could be performed with comparable morbidity 
to primary CND, it was associated with some serious complications. The short and long-term 
disease control appeared moderate with approximately one-tenth having undetectable sTg level 
6-month after ablation and one-third remaining clinically disease-free after 10 years 
 
Key words: papillary thyroid carcinoma; thyroidectomy; reoperation; central neck dissection; 
recurrent laryngeal nerve; postoperative hypoparathyroidism
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INTRODUCTION 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma and the age-
adjusted incidence has doubled in the last 25 years.1,2 Despite its good prognosis with 10-year 
cancer-specific survival (CSS) above 90%, locoregional recurrence is relatively common.3 Local 
recurrences are found in 5-20% of patients with PTC, of which two thirds are localized in the 
cervical lymph nodes.3 With the availability of ultrasensitive thyroglobulin (Tg) assays and high 
resolution ultrasonography (USG), the identification of asymptomatic, small-volume metastatic 
cervical lymph nodes has become relatively common.4,5 Despite this, the benefit of surgically 
removing these small nodes remains unclear.4 In fact, the revised American Thyroid Association 
recommends only surgical removal of clinically significant (i.e. size > 8mm in diameter) 
metastatic lymph nodes or recurrent disease to prevent future locoregional complications.4 
However, unlike the lateral compartment, untreated persistent / recurrent disease in the central 
compartment is associated with a significant higher risk of long-term morbidity, including loss or 
change in voice quality and swallowing because of the proximity of the recurrent laryngeal nerve 
(RLN) and the aerodigastic tract.6-8 Furthermore, it increases the risk of cancer-specific deaths.6-8 
Therefore, reoperative surgery in the central compartment (RCND) is usually indicated. 
Although most studies have reported relatively acceptable morbidity with some reporting rates 
similar to primary CND, morbidity does vary between studies and is subjected to publication 
bias.6,9-15 Furthermore, the efficacy of RCND in disease control remains relatively unclear as not 
all studies have explicitly analyzed this outcome, particularly in terms of postoperative 
thyroglobulin levels and survivals.5 As a result, our study aimed to review our experience in 
RCND specifically evaluating  the surgical morbidity and efficacy in disease control.
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PATIENTS AND METHODS 
Patients 
From 1992 to 2011, 1586 patients underwent surgery for histologically-proven PTC. Of these, 50 
(3.2%) patients underwent RCND for persistent / recurrent PTC. We defined RCND as a 
comprehensive bilateral central lymph node dissection in a previously dissected central 
compartment. Patients who had initial thyroidectomy without CND were included.  We also 
included those who developed recurrent tumor in the thyroid remnant and those with previously 
non-enlarged metastatic central neck lymph nodes or central neck lymph nodes which were not 
completely removed in the initial operation. However, patients who underwent re-excision of a 
normal / non-tumorous thyroid remnant or excision of lymph nodes only (i.e. “berry-picking”) in 
a previously operated central compartment were not included. For patients who underwent ≥1 
RCND, for simplicity, only the earliest reoperation was analyzed. To have a more meaningful 
comparison of surgical morbidity and disease outcomes of RCND, these 50 patients who had 
RCND were compared according to a 1.5:1 match with patients undergoing a therapeutic 
primary CND during the same period (i.e. those who underwent CND at the time of 
thyroidectomy). Over this period, there were 159 patients who had undergone a therapeutic 
primary CND. Those who underwent prophylactic CND were not included. The two groups were 
matched according to the following criteria: sex, age, tumor size and initial tumor stage. 
Matching was performed blind to the morbidity and disease outcome of each patient. Primary 
CND consisted of bilateral removal of clinically-involved central lymph nodes (cN1) at the time 
of the initial total thyroidectomy (TT). 
Indications and technique for RCND 
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Persistent / recurrent disease was diagnosed using a combination of clinical evidence, USG, fine 
needle aspiration (FNA), post-radioiodine (RAI) scan, computed tomography (CT), magnetic 
resonance imaging (MRI) and /or FDG-PET/CT scan. In general, for patients with bulky (>8-
10mm) and / or progressive central disease, RCND was preferred whereas for those with non-
bulky (<5-8mm) and non-progressive central disease, close observation by regular USG was 
preferred. 
In terms of surgical technique, the incision was generally made along the previous thyroidectomy 
incision. If required, the incision was extended laterally. A subplatysmal flap was elevated 
superiorly and inferiorly elevating the neck flaps. The inferior neck flap was usually elevated 
well below the sternal notch for easier retraction. To have a better surgical exposure, the upper 
part of the strap muscles on the side of reoperation was divided. For all cases, the RLN was 
identified first and traced along its course before proceeding to CND. In a densely scarred field, 
the intraoperative nerve stimulator probe was sometimes used for mapping out the course of the 
RLN.16 Gentle dissection of the RLN was taken to dissect it from the central neck lymph nodes. 
The rest of the procedure was performed similar to a primary CND which had been described 
previously.17 
Treatment protocol 
Details of the treatment and follow-up protocols had been described previously.18 Two months 
after surgery, a standard ablative RAI dose of 3 giga-Becquerels (GBq) or 80 millicuries (mCi) 
was given after LT4 withdrawal or with recombinant TSH (rTSH). TSH-suppressive LT4 
treatment was commenced immediately afterwards. External beam radiotherapy (ERT) to the 
neck was given to patients with extensive extrathyroidal tumor extension, incomplete resection, 
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and/or extracapsular lymph node metastasis (40 Gy over 3 weeks for adjuvant treatment and 50 
Gy over 4 weeks for gross residual disease). All treatment decisions were made at a multi-
disciplinary meeting. 
Complications 
Both vocal cords were examined preoperatively and within 1 week of surgery. Any reduced cord 
movement was recorded as vocal cord palsy. Those with palsy were examined every 6-8 weeks 
by otolaryngologists in the first 6 months. The presence of palsy lasting > 6 months was regarded 
as permanent. To calculate vocal cord palsy rates, the number of nerves at risk was used as 
denominator. Calcium +/- calcitriol supplements were given selectively.  For 
hypoparathyroidism, those taking calcium +/- calcitriol supplements were slowly weaned off 
their supplements. By definition, those who discontinued all supplements in the presence of 
normocalcemia ≤ 6 months after surgery were regarded as temporary hypoparathyroidism 
whereas those who continued for >6 months were categorized as permanent hypoparathyroidism. 
Surveillance 
All data including disease status and cause of death were prospectively collected after 1995. 
Follow-up visit was conducted at 3-monthly interval in the first 2 years, 6 monthly for the 
subsequent 3 years and annually thereafter. In addition to clinical examination, USG neck and Tg 
levels were performed at each follow-up. All Tg levels were measured in the same laboratory 
using the same immunometric assay. The assay used was the Immulite 2000 (Diagnostic 
Products Corp. Roche, Los Angeles, CA). This was calibrated against the CRM- 457 standard. A 
stimulated Tg (sTg) < 2.0ug/L was considered undetectable. Normal reference range was <0.5 – 
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55 ug/L and sensitivity was <0.2 ug/L. Clinical recurrences were diagnosed by USG, CT/ MRI 
or FDG-PET scan and confirmed by FNAC. Survival data including the cause of death were 
retrieved from the territory-wide computerized medical system and from death certificates or 
postmortem examinations.  
Statistical analysis 
Statistical analysis was performed by chi-square or Fisher’s Exact test to compare categorical 
variables, and Mann-Whitney U test was used to compare continuous variables between groups. 
Continuous variables were expressed as medians with ranges. In the RCND group, survival and 
duration of follow-up were calculated from the time of RCND to the date of last follow-up or 
death while in the primary CND group, it was taken from the time of primary CND. Disease-free 
survival (DFS) and CSS were calculated by the Kaplan-Meier method. Survival outcomes were 
compared using the log-rank test. All statistical analyses were performed using SPSS version 
18.0 (SPSS, Inc., Chicago, IL, USA). 
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RESULTS 
Table 1 shows the baseline characteristics of the 50 patients who underwent RCND. Thirty-four 
patients underwent initial operation at our institution whereas the other 16 patients had initial 
operation performed elsewhere. All patients received 3GBq RAI ablation after initial operation 
while only one (2.0%) patient received ERT following initial operation. All had imageable one-
sided recurrence in the central compartment and of these, 7 (14.0%) patients had palpable central 
neck recurrence. The USG and FDG-PET/CT was the most common combination for disease 
staging before surgery. Two (4.0%) patients had evidence of distant metastases at the time of 
RCND.  Of the 20 patients who had RCND only, 2 also underwent a mediastinal clearance via a 
sternotomy for bulky upper mediastinal disease. Of the 6 patients who had tumor remnant 
excision, 4 patients had tumor remnant excision and CND while 2 patients had tumor remnant 
excision, CND and lateral selective neck dissection. Two patients in this tumor remnant excision 
subgroup also required tumor shaving from the trachea. The common sites for persistent / 
recurrent disease were adjacent to the RLN (38.0%), followed by paratracheal (34.0%) and para-
esophageal (14.0%). Of the 20 (i.e. 12+8) patients who underwent CND at the initial operation 
and developed subsequent detectable recurrence on one side, 6 (30.0%) patients had microscopic 
or occult positive nodes on the other side.  
Table 2 shows a comparison of clinicopathologic factors between those who underwent primary 
CND and RCND. As expected, age, sex, tumor size and primary tumor stage were comparable 
between the two groups. In terms of pathologic findings, the median number of central lymph 
nodes (CLNs) retrieved (7 vs. 7, p=0.489), positive CLNs examined (3 vs. 4, p=0.095) and 
lymph node ratio (LNR) (52.3% vs. 57.2%, p=0.512) were similar between the two groups The 
incidence of incidental parathyroid gland on excised specimen was also similar between the two 
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groups (17.3% vs. 18.0%, p=0.936) but the presence of extra-nodal extension was significantly 
more frequent in the RCND than primary CND (36.0% vs. 14.7%, p=0.010). Also the median 
size of metastatic central lymph node in RCND was also significantly larger than primary CND 
(15mm vs. 12mm, p<0.001). 
Table 3 shows a comparison of morbidity and disease outcomes between primary CND and 
RCND. The temporary hypoparathyroidism rate was comparable between the two groups (8.0% 
vs. 14.0%, p=0.383). After excluding the 8 patients already taking calcium supplements before 
surgery in the RCND group, the permanent hypoparathyroidism rate was similar between the two 
groups (1.3% vs. 0.0%, p=1.000). The number of nerves-at-risk in primary CND and RCND was 
150 and 100, respectively. After excluding the 6 patients with preoperative unilateral vocal cord 
palsy (due to tumor invasion to RLN), both temporary and permanent vocal cord palsy rates were 
similar between the two groups. Apart from hypoparathyroidism and vocal cord palsy, 2 patients 
in the RCND group suffered cervical esophageal injury, one of which was recognized intra-
operatively and was repaired while the other was only recognized 2 days after surgery and 
required reoperation. In retrospect, both patients had incomplete primary tumor excision at the 
initial operation and both tumors recurred and partially invaded into the esophageal wall. The 
total morbidity rate was similar between two groups (20.0% vs. 28.0%, p=0.210). There was no 
in-hospital mortality. Within the RCND group, the temporary hypoparathyroidism and vocal 
cord palsy rates were comparable between those who had previous TT and those who had 
previous TT and neck dissection (4/27 vs. 3/23, p=1.000 and 3/27 vs. 3/23, p=1.000, 
respectively). 
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All patients after secondary CND received RAI ablation and 3 patients received additional ERT. 
The rate of detectable sTg (i.e. sTg ≥ 2ng/mL) was significantly higher in the secondary CND 
group (p=0.001). Despite the shorter median duration of follow-up, the number of postoperative 
recurrences was significantly higher in the secondary than primary group (26.0% vs. 6.7%, 
p=0.008) and also tended more likely to undergo subsequent reoperation than primary CND 
group (12.0% vs. 2.7%,p=0.066). The number of central compartment recurrences was also 
significantly higher in the secondary than primary group (12.0% vs. 0.0%, p=0.011). Other sites 
of recurrence were similar between the two groups.  
Figure 1 shows the DFS survival curves between those who underwent primary and secondary 
groups. The 5-year and 10-year DFS between patients who underwent primary and secondary 
CND were 91.8% and 91.8% vs. 71.2% and 35.6%, respectively, p=0.001. There were 8 patients 
who developed locoregional recurrence after RCND. By logistic regression, age at diagnosis 
(p=0.386), sex (p=0.577), primary tumor size (p=0.346), TNM staging (p=0.637), number of 
CLNs retrieved (p=0.707), number of positive CLNs retrieved (p=0.632), LNR (p=0.819), extra-
nodal extension (p=0.512) and size of CLN (p=0.454) were not significant factors for 
locoregional recurrence after RCND.  
Figure 2 shows the CSS curves between those who underwent primary and secondary groups. 
The 5-year and 10-year CSS between patients who underwent primary and secondary groups 
were 98.5%% and 98.5% vs. 88.3% and 82.0%, respectively, p=0.001.
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DISCUSSION 
Consistent to previous studies, our data suggested that in well-selected cases, the morbidity of 
RCND for persistent / recurrent PTC was comparable to that of primary CND.9,10 Table 4 shows 
a comparison of rate of complications, sTg and locoregional recurrence between our study and 
others. After excluding patients with preexisting hypoparathyroidism or vocal cord palsy before 
RCND, the temporary and permanent rates of these complications were similar between the two 
groups. However, it is worth noting that two (4.0%) patients in the RCND group did suffer 
iatrogenic injury to the cervical esophagus. Although one injury was recognized and repaired 
intraoperatively without any sequels, the other injury was missed and only recognized 2 days 
after surgery. That patient later developed an esophago-cutaneous fistula requiring a prolonged 
period of hospital stay. In retrospect, these two injuries were probably a direct result of the tumor 
invading into part of the esophagus. Therefore, in our opinion, although serious complications 
such as esophageal injury could result after RCND, the total morbidity of RCND appeared 
relatively acceptable and comparable to primary CND (28.0% vs. 20.0%, p=0.210). Nevertheless, 
the decision for RCND should not be taken lightly and should be based on weighing the risks 
and benefits of surgical reoperation with the risk of disease. 
The other aspect which our study evaluated was disease control after RCND and that was 
assessed both biochemically and clinically. Using sTg <2ng/mL as biochemical undetectable 
disease, the RCND group achieved a significantly lower rate of undetectable post-ablation sTg 
than primary CND group (12.0% vs. 52.0%, p<0.001). This was despite both groups were 
matched for sex, age, tumor size and initial tumor stage. However, this finding was not entirely 
unexpected because the surgical indication between the two groups was quite different. For the 
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RCND group, approximately half were performed due to the bulkiness of the disease and the 
other half were due to disease progression whereas primary CND was usually done when there 
was clinical evidence of central lymph node metastasis (i.e. cN1) at the time of the initial TT. As 
a result, the RCND group had more advanced nodal disease as reflected by the greater incidence 
of extra-nodal extension (36.0% vs. 14.7%, p=0.010) and the size of metastatic central lymph 
nodes (17mm vs. 12mm, p<0.001) than primary CND group. Similarly, the incidence of 
preoperative unilateral vocal cord palsy in the RCND group was higher than that of the primary 
CND group (14.0% vs. 0.0%).  
Apart from the undetectable post-ablation sTg, the overall recurrence rate in the RCND group 
was also significantly higher than the primary CND group (26.0% vs. 6.7%, p=0.008). Although 
it might appear high, they were relatively comparable to other similar series.6,8,10,15 Of the 13 
clinically detectable recurrences in the RCND group, 8 (61.5%) occurred either in the central or 
central and lateral compartments. In contrast, of the 5 clinical recurrences in the primary CND 
group, only one (20.0%) occurred in the central compartment. This implied the fact that despite 
performing a fairly comprehensive RCND, the disease control in the central compartment 
remained relatively moderate. It is also worth noting that of the 13 clinical recurrences, 5 (38.5%) 
(excluding the 2 patients with distant metastases before reoperation) developed distant disease. 
In fact, both 10-year DFS and CSS were significantly worse in the RCND group than the 
primary group (35.6% vs. 91.8%, p=0.001 and 82.0% vs. 98.5%, p=0.001). These findings 
underlined the importance of administrating adjuvant treatment after RCND as this group not 
only tended to recur locally but also in distant sites. 
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Despite these findings, our results should be interpreted cautiously because firstly, the surgical 
indication and selection for primary and RCND were very different (i.e. selection bias).  For 
example, primary CND was done simply as part of the initial operation whereas the reason for 
RCND was to “prevent” future morbidities because of the bulkiness or progression of the central 
disease. We would also like to acknowledge that the RCND group was rather heterogeneous in 
terms of patients receiving different extent of initial operation prior to reoperation and different 
extent of persistent/recurrent disease. There were some patients who only had TT without CND 
while others had TT with CND as initial procedure. Ideally, these patients should have been 
separately analyzed but since the number of patients was few, we did not further perform 
subgroup analyses. Nevertheless, based on our data, the temporary hypoparathyroidism and 
vocal cord palsy rates appeared similar between the two subgroups. Also since this was a 
retrospective study, selection biases could not be completely ruled out. 
Despite our findings, since RCND remains the only effective treatment in bulky and progressive 
central disease to prevent complications, the indication for RCND should remain unchanged 
despite the relatively poor long-term disease control. It remains unclear if performing RCND at 
an earlier stage (i.e. before disease becoming > 8-10mm or progressive) would significantly 
reduce the morbidity and improve the long-term disease outcomes.  
CONCLUSIONS 
Overall, in well selected cases, RCND for persistent / recurrent PTC could be performed with 
comparable morbidity to that of primary CND. However, it may be associated with some serious 
complications depending on the finding of the initial operation. In terms of disease control after 
RCND, only approximately one-tenth had undetectable post-ablation sTg level at 6 months after 
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surgery and one-third were clinically disease-free after 10 years.
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Table 1. Baseline characteristics of the 50 patients who underwent reoperative surgery in central 
compartment (RCND) 
Characteristics Median or number of 
patients 
Range or % 
Age at RCND (years) 54.2 18.9 – 85.1 
Sex 
- Male 
- Female 
 
15 
35 
 
30.0 
70.0 
Main surgical indication for RCND 
- Bulky disease 
- Progressive 
 
26 
24 
 
52.0 
48.0 
Type and extent of initial operation 
- TT 
- TT + CND 
- TT + CND + SND 
- TT + SND 
 
27 
12 
8 
3 
 
54.0 
24.0 
16.0 
6.0 
Initial primary TNM tumor stage 
- Stage I 
- Stage II 
- Stage III 
- Stage IV 
 
14 
8 
28 
0 
 
28.0 
16.0 
56.0 
0.0 
Time interval from initial operation to RCND 
(months) 
36.4 12.7 – 363.0 
Imaging before RCND 
- USG + FDG/PET 
- USG + CT / MRI 
- USG alone 
 
33 
8 
9 
 
66.0 
16.0 
18.0 
Type and extent of RCND 
- Excision of tumor remnant# + neck dissection 
 
6 
 
12.0 
20 
 
- CND only* 
- CND + SND 
20 
24 
40.0 
48.0 
Site of persistent/recurrent disease 
- Pre-tracheal area 
- Para-tracheal area 
- Para-esophageal area 
- Adjacent to the RLN 
- Upper mediastinal area 
 
4 
17 
7 
19 
3 
 
8.0 
34.0 
14.0 
38.0 
6.0 
Abbreviations: TT = total thyroidectomy; CND = central neck dissection; SND = selective lateral 
neck dissection; USG = ultrasonography; FDG-PET = 18F-fluorodeoxyglucose positron 
emission tomography; CT = computed tomography; MRI = magnetic resonance imaging; RLN = 
recurrent laryngeal nerve 
# two patients had tracheal shaving 
*two patients required sternotomy and mediastinal clearance 
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Table 2. A comparison of clinicopathologic factors between primary central neck dissection 
(CND) and reoperative surgery in central compartment (RCND) 
Variable Primary CND (n=75) RCND (n=50) p-value 
Age at surgery (years)* 47.9 (7.3 – 84.4) 54.2 (18.9 – 85.1) 0.234 
Sex* 
- Male 
- Female 
 
17 (22.7) 
58 (77.3) 
 
15 (30.0) 
35 (70.0) 
0.484 
Primary tumor size (mm)* 20 (2 – 85) 21 (3 – 67) 0.556 
Initial primary TNM tumor stage* 
- Stage I 
- Stage II 
- Stage III 
- Stage IV 
 
23 (30.7) 
13 (17.3) 
39 (52.0) 
0 (0.0) 
 
14 (28.0) 
8 (16.0) 
28 (56.0) 
0 (0.0) 
0.972 
Concomitant SND 
- Yes 
- No 
 
41 (54.7) 
34 (45.3) 
 
26 (52.0) 
24 (48.0) 
0.805 
Pathologic findings 
- Number of CLNs retrieved 
- Number of positive CLNs retrieved 
- Lymph node ratio (%) 
 
7 (3 – 26) 
3 (1 – 7) 
52.3 (12.5 – 100.0) 
 
7 (3 – 18) 
4 (1 – 14) 
57.2 (14.3 – 100.0) 
 
0.489 
0.095 
0.512 
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- Incidental parathyroid in specimen 
- Presence of extranodal extension 
- Size of metastatic CLN (mm) 
13 (17.3) 
11 (14.7) 
12 (3 – 35) 
 9 (18.0) 
18 (36.0) 
15 (7 – 30) 
0.936 
0.010 
<0.001 
Radioiodine ablation 75 (100.0) 50 (100.0) - 
Postoperative ERT 2 (2.7) 6 (12.0) 0.115 
Bold signifies p<0.05 (i.e. statistically significant) 
*matching was performed blind to morbidity and disease outcome 
Abbreviations: CND = central neck dissection; SND = selective lateral neck dissection; CLN = 
central lymph node; ERT = external beam radiotherapy
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Table 3. A comparison of morbidity and disease outcomes between primary central neck 
dissection (CND) and reoperative surgery in central compartment (RCND) 
 Primary CND (n=75) RCND (n=50) p-value 
Postoperative hypoparathyroidism 
- Temporary 
- Permanent 
 
6 (8.0) 
1 (1.3) 
 
7 (14.0) 
0 (0.0)* 
 
0.383 
1.000 
Vocal cord palsy+ 
- Temporary 
- Permanent 
 
6 (4.0) 
2 (1.3) 
 
6 (6.0) 
1 (1.0)# 
 
0.553 
0.570 
Esophageal injury 0 (0.0) 2 (4.0) 0.172 
Total morbidity^ 15 (20.0) 14 (28.0) 0.210 
Postoperative sTg level 
- After ablation (ng/mL) 
- <2 ng/mL 
- ≥2 ng/mL 
 
1.9 (<0.2 – 154) 
39 (52.0) 
36 (48.0) 
 
28.5 (<0.2 – 130) 
6 (12.0) 
44 (88.0) 
 
<0.001 
0.001 
0.001 
Follow-up time since CND 78.2 (14.3 – 360.1) 42.0 (15.1 – 160.7) 0.170 
Number of clinical recurrences 
- Central recurrence 
- Central and lateral recurrences 
- Lateral recurrence 
- Distant +/- local recurrences 
5 (6.7) 
0 (0.0) 
1 (1.3) 
2 (2.7) 
2 (2.7) 
13 (26.0) 
6 (12.0) 
2 (4.0) 
0 (0.0) 
5 (10.0) 
0.008 
0.011 
0.570 
0.510 
0.127 
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Needing subsequent reoperation 2 (2.7) 6 (12.0) 0.066 
Disease status at last follow-up 
- Alive without disease 
- Alive with disease   
- Died 
 
71 (94.7) 
2 (2.7) 
2 (2.7) 
 
31 (72.0) 
15 (30.0) 
5 (10.0) 
<0.001 
Abbreviation: sTg = stimulated thyroglobulin 
* after excluding 8 patients requiring calcium and/or calcitriol supplements before RCND 
# after excluding 6 patients with preoperative vocal cord palsy 
+ percentages calculated from number of nerves at risk 
^those with one or more complications were counted as one 
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Table 4. A comparison of vocal cord palsy (VCP), hypocalcemia (hypoCa), rate of detectable stimulated thyroglobulin (sTg) and 
locoregional recurrence (LRR) between the present study and other similar series in reoperative surgery of the central compartment 
(RCND) 
First author (size 
of cohort) 
Year of 
publication 
Temporary 
VCP (%) 
Permanent 
VCP (%) 
Temporary 
hypoCa (%) 
Permanent 
hypoCa (%) 
Rate of detectable 
(≥2ng/mL) sTg 
after RCND (%) 
LRR after 
RCND (%) 
Kim11 (n=20) 2004 0 (0.0) 0 (0.0) 3 (16.7) 1 (5.6) - 1 (5.0) 
Farrag7 (n=33) 2007 7 (21.2) 0 (0.0) 2 (6.1) 0 (0.0) 6.1* 0 (0.0) 
Alvarado9 (n=23) 2009 1 (3.3) 0 (0.0) 2 (8.7) 0 (0.0) - - 
Ondik13 (n=44) 2009 1 (2.1) 3 (6.4) 5 (11.4) 4 (9.1) - - 
Clayman19 (n=63) 2009 1 (1.6) 0 (0.0) 12 (19.0) 3 (4.8) - - 
Shen10 (n=106) 2010 5 (4.7) 2 (1.9) 25 (23.6) 1 (0.9) - 31 (29.2) 
Roh12 (n=45) 2011 4 (5.8) 1 (1.4) 19 (46.3) 2 (4.9) - 1 (2.2) 
Shah15 (n=82) 2012 3 (2.3) 3 (2.3) 17 (20.7) 6 (7.3) 48.5 17 (20.7) 
Present study 
(n=50) 
- 6 (6.0) 1 (1.0) 7 (14.0) 0 (0.0) 88.0 8 (16.0) 
Note: The rate of VCP was calculated based on number of nerves at risk and those with the involved recurrent laryngeal nerve 
requiring intentional resection were excluded. Also rate of hypoCa was calculated based on patients with normal preoperative 
parathyroid function. 
*basal thyroglobulin 
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LEGENDS 
Figure 1. The disease-free survival curves between those who underwent primary central neck 
dissection (primary CND) and reoperative surgery in the central compartment (RCND) 
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Figure 2. The cancer-specific survival curves between those who underwent primary central neck 
dissection (primary CND) and reoperative surgery in the central compartment (RCND). 
 
